<!DOCTYPE html>
<html lang="fa">
 <meta content="text/html;charset=utf-8" http-equiv="content-type"/>
 <head>
  <title>
   Cancer of the ovary, fallopian tube, and peritoneum: Surgical options for recurrent cancer
  </title>
  <link href="d/css/1.css" rel="stylesheet"/>
 </head>
 <body>
  <!-- Start Main Menu Area -->
  <br/>
  <br/>
  <br/>
  <br/>
  <div class="container">
   <div class="row">
   </div>
  </div>
  <section class="teacher-area ptb-10">
   <div class="container">
   </div>
   <section class="course-details-area ptb-60">
    <div class="container">
     <div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
      <h1 style="text-align:center">
       Cancer of the ovary, fallopian tube, and peritoneum: Surgical options for recurrent cancer
      </h1>
      <div class="utdArticleSection utdStyle" id="topicContent">
       <div id="topicTitle">
        Cancer of the ovary, fallopian tube, and peritoneum: Surgical options for recurrent cancer
       </div>
       <div class="authorSectionElem">
        <div class="authorsElementsLeft">
         <dl id="topicContributors">
          <dt>
           <span>
           </span>
           Authors:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Dennis S Chi, MD
           </a>
          </dd>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Karin K Shih, MD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Section Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Barbara Goff, MD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Deputy Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Alana Chakrabarti, MD
           </a>
          </dd>
         </dl>
        </div>
        <div class="authorsElementsRight">
         <div id="literatureReviewDate">
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             Literature review current through:
            </span>
            Jan 2024.
           </bdi>
          </div>
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             This topic last updated:
            </span>
            Jan 26, 2023.
           </bdi>
          </div>
         </div>
        </div>
       </div>
       <div id="topicWhatsNewContainer">
       </div>
       <div id="topicText">
        <p class="headingAnchor" id="H566579374">
         <span class="h1">
          INTRODUCTION
         </span>
         <span class="headingEndMark">
          —
         </span>
         The majority of ovarian cancer patients experience recurrence of disease [
         <a href="#rid1">
          1
         </a>
         ]. The pattern varies from isolated nodal disease to isolated peritoneal disease to peritoneal carcinomatosis. Extra-abdominal sites of recurrence are uncommon. Most patients with recurrent ovarian cancer are treated with chemotherapy alone. Surgical treatment is reserved for a select group of patients.
        </p>
        <p>
         Surgery for recurrent ovarian cancer is reviewed here. Monitoring patients for recurrence and medical treatment of recurrence are discussed separately.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/17007.html" rel="external">
          "Approach to survivors of epithelial ovarian, fallopian tube, or peritoneal carcinoma", section on 'Post-treatment surveillance'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/3240.html" rel="external">
          "Medical treatment for relapsed epithelial ovarian, fallopian tube, or peritoneal cancer: Platinum-resistant disease"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/16755.html" rel="external">
          "Medical treatment for relapsed epithelial ovarian, fallopian tube, or peritoneal cancer: Platinum-sensitive disease"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H566579397">
         <span class="h1">
          SCOPE AND GOALS OF SURGERY
         </span>
         <span class="headingEndMark">
          —
         </span>
         Surgery for recurrent ovarian cancer may involve secondary (rarely tertiary or quaternary) cytoreductive surgery, partial liver resection, splenectomy, or surgery for bowel obstruction. The goal of additional cytoreductive surgery is to prolong survival by resecting all visible disease (complete gross [R0] resection). The goal of surgery for bowel obstruction is palliative: to improve quality of life.
        </p>
        <p class="headingAnchor" id="H3597334990">
         <span class="h1">
          CANDIDATES
         </span>
         <span class="headingEndMark">
          —
         </span>
         In our practice, we apply the Memorial Sloan Kettering Cancer Center (MSKCC) criteria to determine if patients should be offered secondary cytoreductive surgery for recurrent ovarian cancer  (
         <a class="graphic graphic_table graphicRef126425" href="/z/d/graphic/126425.html" rel="external">
          table 1
         </a>
         ).
        </p>
        <p>
         In general, candidates for secondary cytoreduction are patients with limited sites of recurrence and platinum-sensitive disease, which is defined as a recurrence beyond six months after completion of adjuvant platinum-based chemotherapy. Patients with an early recurrence (platinum-resistant disease) often have a decreased response to additional chemotherapy; thus, they are not ideal candidates for secondary cytoreduction. (See
         <a class="medical medical_review" href="/z/d/html/16755.html" rel="external">
          "Medical treatment for relapsed epithelial ovarian, fallopian tube, or peritoneal cancer: Platinum-sensitive disease"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/3240.html" rel="external">
          "Medical treatment for relapsed epithelial ovarian, fallopian tube, or peritoneal cancer: Platinum-resistant disease"
         </a>
         .)
        </p>
        <p>
         Several studies have supported the ability to achieve complete secondary cytoreduction as a key prognostic factor for survival [
         <a href="#rid2">
          2-12
         </a>
         ]. However, preoperatively predicting whether complete secondary cytoreduction will be possible remains a challenge.
        </p>
        <p class="headingAnchor" id="H3557571845">
         <span class="h1">
          PREDICTING SUCCESSFUL DISEASE RESECTION
         </span>
         <span class="headingEndMark">
          —
         </span>
         Risk models are often applied in determining which patients are candidates for secondary surgical cytoreduction. Other factors, such as imaging findings as well as laparoscopy, are also utilized to determine whether sites of recurrence are limited and potentially resectable.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Findings at the time of surgery usually correlate with imaging findings. If there is clinical concern for recurrent disease (patient-reported symptoms or elevation in serum cancer antigen 125 [CA 125]), imaging studies, such as chest/abdominal/pelvic computed tomography (CT) or magnetic resonance imaging, should be obtained to evaluate for presence and sites of recurrent disease. Positron emission tomography/CT scans can be very helpful prior to surgery to rule out disease that may be unresectable, such as mediastinal nodes.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Diagnostic laparoscopy may be useful for distinguishing patients who can be optimally debulked at secondary surgery, but data are limited [
         <a href="#rid13">
          13,14
         </a>
         ]. This follows the paradigm applied in primary disease to assess feasibility of successful disease resection. In our experience, laparoscopy is not routinely utilized in secondary cytoreductive surgery.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Prognostic models have been developed to predict the likelihood of complete secondary cytoreductive surgery in patients with recurrent ovarian cancer.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         One study developed an international model (iMODEL) based on individual data from 1075 patients with recurrent ovarian cancer from seven international centers [
         <a href="#rid15">
          15
         </a>
         ]. Complete secondary cytoreduction was achieved in 53 percent of patients with a low score and 20 percent of patients with a high score for the following variables: International Federation of Gynecology and Obstetrics (FIGO) stage at initial diagnosis (I/II versus III/IV), residual disease after primary cytoreduction (absent versus present), progression-free interval (≥16 versus &lt;16 months), performance status, serum CA 125 at recurrence (≤105 versus &gt;105 U/mL), and ascites at recurrence (absent versus present). In external validation, the sensitivity and specificity were 83.3 and 57.6 percent, respectively.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         The DESKTOP OVAR trial (Descriptive Evaluation of preoperative Selection KriTeria for OPerability in recurrent OVARian Cancer) evaluated an Arbeitsgemeinschaft Gynaekologische Onkologie (AGO) score for predicting complete gross resection (R0) at secondary cytoreductive surgery. A positive AGO score was characterized by Eastern Cooperative Oncology Group (ECOG) performance status of 0, ascites &lt;500 mL, and complete resection at initial surgery [
         <a href="#rid16">
          16
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         The DESKTOP II trial applied the AGO score to prospectively evaluate patients with recurrent disease (after a platinum-free interval of &gt;6 months) for secondary cytoreductive surgery [
         <a href="#rid17">
          17
         </a>
         ]. Complete gross resection (R0) was achieved in 76 percent of patients with a positive AGO score.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Parallel with the AGO DESKTOP trials, a study comparing Memorial Sloan Kettering Cancer Center (MSKCC) criteria (disease-free interval, single versus multiple sites of recurrence versus carcinomatosis) to predict complete gross resection with the AGO model reported the complete gross resection (R0) rate was 86 percent for both [
         <a href="#rid18">
          18
         </a>
         ]. However, MSKCC criteria rendered a higher proportion of patients eligible for secondary cytoreductive surgery (98 versus 46 percent).
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H675071018">
         <span class="h1">
          PROCEDURE
         </span>
         <span class="headingEndMark">
          —
         </span>
         The goal of surgery in recurrent ovarian, fallopian tube, or peritoneal cancer is complete gross resection.
        </p>
        <p class="headingAnchor" id="H4113604136">
         <span class="h2">
          Secondary cytoreductive surgery
         </span>
         <span class="headingEndMark">
          —
         </span>
         The approach to secondary cytoreductive surgery depends on the distribution of disease on preoperative imaging. The potential for adhesions and distortion of abdominal and pelvic anatomy due to prior surgery also needs to be considered in making this decision. An open approach is always reasonable, but if disease appears to be limited to a solitary site, a laparoscopic or robotic approach may be feasible, depending on the surgeon's expertise. Rarely, recurrence is limited to a single lymph node, termed isolated lymph node relapse. Prolonged post-relapse survival and overall survival appear to be more likely in these cases than with extranodal relapse [
         <a href="#rid19">
          19
         </a>
         ].
        </p>
        <p>
         Hyperthermic intraperitoneal chemotherapy (HIPEC) at the time of surgical cytoreduction is an investigational modality for treating patients with recurrent ovarian cancer and its clinical benefit is unclear. In a randomized phase II trial including 98 patients with recurrent ovarian cancer, patients receiving
         <a class="drug drug_general" data-topicid="9202" href="/z/d/drug information/9202.html" rel="external">
          carboplatin
         </a>
         HIPEC followed by five cycles of carboplatin-based chemotherapy versus no HIPEC and six cycles of carboplatin-based chemotherapy had similar median overall survival (52.5 and 59.7 months, respectively) [
         <a href="#rid20">
          20
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/16755.html" rel="external">
          "Medical treatment for relapsed epithelial ovarian, fallopian tube, or peritoneal cancer: Platinum-sensitive disease", section on 'Heated intraperitoneal chemotherapy'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H2943717676">
         <span class="h2">
          Tertiary cytoreductive surgery
         </span>
         <span class="headingEndMark">
          —
         </span>
         After secondary cytoreductive surgery, few data are available on the role of additional cytoreductive surgery for recurrent ovarian cancer [
         <a href="#rid21">
          21-24
         </a>
         ]. The survival benefit appears to be limited to patients in whom the procedure results in no residual disease. In the largest series, a retrospective multicenter study of 406 patients, median overall survival in patients with no versus some gross residual disease after tertiary cytoreduction was 49 and 12 months, respectively [
         <a href="#rid23">
          23
         </a>
         ]. Survival benefit also appears more favorable in those with high grade serous ovarian cancer. In a subsequent retrospective review including 114 patients with recurrent epithelial ovarian cancer undergoing tertiary cytoreduction, patients with high-grade serous ovarian cancer and a single site of recurrence who were ≥2 years from secondary cytoreduction had the longest survival (median 79.5 months) [
         <a href="#rid24">
          24
         </a>
         ].
        </p>
        <p>
         Independent factors predictive of complete cytoreduction in these patients include limited extent of disease (in particular, a single site of disease), lack of carcinomatosis, and no extrapelvic tumor involvement [
         <a href="#rid22">
          22,25
         </a>
         ].
        </p>
        <p>
         Beyond the tertiary setting, data are even more limited [
         <a href="#rid25">
          25,26
         </a>
         ]. In the largest series, which included 49 patients, mean overall survival for patients without versus any residual tumor after quaternary cytoreduction was 43.0 and 13.4 months, respectively [
         <a href="#rid26">
          26
         </a>
         ]. Multifocal tumor dissemination was predictive of incomplete tumor resection, higher operative morbidity, and lower survival in multivariate analysis, whereas postoperative systemic chemotherapy improved overall survival.
        </p>
        <p class="headingAnchor" id="H566579404">
         <span class="h2">
          Partial liver resection
         </span>
         <span class="headingEndMark">
          —
         </span>
         In three retrospective reports from single institutions, a total of 68 patients underwent hepatic resection for recurrent ovarian cancer along with resection of other gross disease [
         <a href="#rid27">
          27-29
         </a>
         ]. Median survival was approximately 26, 38, and 62 months in the three series. Factors associated with longer survival after hepatic resection included negative margin status of the hepatic resection, optimal cytoreduction of nonhepatic disease, pelvic versus abdominal disease, and longer time from initial diagnosis and surgery.
        </p>
        <p class="headingAnchor" id="H566579411">
         <span class="h2">
          Splenectomy
         </span>
         <span class="headingEndMark">
          —
         </span>
         Similar to liver resection, the data on splenectomy in surgery for recurrent ovarian cancer are extremely limited. In one report of six patients with isolated parenchymal splenic metastasis at a median of 57 months after initial surgery and platinum-based chemotherapy for stage III disease, all were alive and free of disease at median follow-up of 25.5 months (range 6 to 65 months) after splenectomy [
         <a href="#rid30">
          30
         </a>
         ].
        </p>
        <p>
         In another report, 24 patients underwent splenectomy as part of secondary cytoreduction; 15 had multiple splenic lesions (8 with disease at other sites), and 9 had a solitary splenic lesion [
         <a href="#rid31">
          31
         </a>
         ]. At a median follow-up of 30 months, median progression-free and overall survival from the time of secondary surgery were 34 and 56 months, respectively.
        </p>
        <p class="headingAnchor" id="H56987426">
         <span class="h2">
          Relief of bowel obstruction
         </span>
         <span class="headingEndMark">
          —
         </span>
         Bowel obstruction in patients with recurrent ovarian cancer is generally related to external compression from carcinomatosis. Less commonly, mesenteric tumor may angulate the bowel and provoke an extramural bowel occlusion. Additionally, pericancer inflammation can lead to adhesions, which can cause obstruction. In some cases, decreased bowel motility results in pseudo-obstruction.
        </p>
        <p>
         Surgery for relief of bowel obstruction is controversial because its benefit appears to be only palliative, it is associated with high rates of morbidity and mortality, and nonoperative alternatives exist (see
         <a class="medical medical_review" href="/z/d/html/85393.html" rel="external">
          "Palliative care of bowel obstruction in cancer patients"
         </a>
         ). In small, single-institution observational studies that have addressed the issue of surgery for bowel obstruction in recurrent ovarian cancer, two-thirds of patients had successful symptom control, but major surgical morbidity occurred in over 20 percent, and perioperative mortality occurred in 4 to 18 percent [
         <a href="#rid32">
          32-36
         </a>
         ]. Median survival after surgery ranged from approximately 3 to 12 months.
        </p>
        <p>
         Surgical palliation of symptoms may be warranted, particularly in the setting of limited peritoneal disease causing a bowel obstruction, but patients should be appropriately counseled regarding the success rates and durability of palliation, as well as the significant morbidity associated with surgery.
        </p>
        <p class="headingAnchor" id="H855932891">
         <span class="h1">
          OUTCOME OF CYTOREDUCTION
         </span>
        </p>
        <p class="headingAnchor" id="H276766509">
         <span class="h2">
          Overall survival
         </span>
         <span class="headingEndMark">
          —
         </span>
         Observational studies have found that cytoreduction to no macroscopic disease is associated with longer overall survival (OS) compared with any visible residual disease, but these studies are likely limited by selection bias [
         <a href="#rid2">
          2,37-40
         </a>
         ]. In a 2013 systematic review of nine studies (seven retrospective) including 1194 patients with recurrent ovarian cancer, complete cytoreduction to no visible disease was associated with a greater than threefold increase in OS compared with leaving any gross residual disease (hazard ratio [HR] 3.59, 95% CI 2.45-5.24) [
         <a href="#rid38">
          38
         </a>
         ]. Most patients received adjuvant chemotherapy as well.
        </p>
        <p>
         Whether secondary (or tertiary) cytoreduction is more effective than chemotherapy is less clear. In a population-based study using Surveillance, Epidemiology, and End Results (SEER) Medicare data from 1635 patients with recurrent ovarian cancer, the median OS of patients treated with surgery plus chemotherapy, chemotherapy alone, and hospice care was 5.4, 4.1, and 2.2 years, respectively [
         <a href="#rid39">
          39
         </a>
         ]. In a subsequent meta-analysis of 36 studies including over 2800 patients with platinum-sensitive recurrent ovarian cancer, secondary surgical cytoreduction with maximal tumor resection resulted in an increase in OS by up to 9 percent (median) [
         <a href="#rid41">
          41
         </a>
         ].
        </p>
        <p>
         Three phase III trials investigating the role of cytoreductive surgery in patients with recurrent ovarian cancer have reported results:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         In Germany, the DESKTOP III trial randomized 407 patients with recurrent platinum-sensitive ovarian cancer who had a first relapse after a platinum-free interval of at least six months and a positive Arbeitsgemeinschaft Gynaekologische Onkologie (AGO) score (which predicts likelihood of a complete surgical resection for recurrent disease and described above (see
         <a class="local">
          'Predicting successful disease resection'
         </a>
         above)) to undergo secondary cytoreductive surgery plus chemotherapy or chemotherapy alone [
         <a href="#rid42">
          42
         </a>
         ]. OS was higher in patients undergoing surgical resection plus chemotherapy versus chemotherapy alone (median 54 versus 46 months; HR 0.75, 95% CI 0.59-0.96) during the 70-month (median) follow-up period. Complete surgical resection was achieved in 76 percent of patients assigned to the surgery group and predicted a better survival outcome than patients in whom complete resection could not be performed (62 versus 28 months, respectively).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Similarly, in China, the Shanghai Gynecologic Oncology Groups' SOC-1 trial randomized 357 patients with platinum-sensitive relapsed epithelial ovarian cancer who had a platinum-free interval of at least six months and potentially resectable disease (as predicted by international model (iMODEL) score (see
         <a class="local">
          'Predicting successful disease resection'
         </a>
         above) and positron emission tomography-computed tomography [PET-CT] imaging) to secondary cytoreduction followed by chemotherapy or chemotherapy alone; 92 percent of patients received their planned therapy [
         <a href="#rid43">
          43
         </a>
         ]. Median progression-free survival was higher for patients who underwent surgery and chemotherapy (17.4 months) versus patients who underwent chemotherapy alone (11.9 months; HR 0.58, 95% CI 0.45-0.74) during the 36-month (median) follow-up period. At the interim analysis, median OS for patients undergoing surgery and chemotherapy versus chemotherapy alone was 58 and 54 months, respectively (HR 0.82, 95% CI 0.57-1.19); long-term survival data were immature at the interim analysis.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         In the United States, the Gynecologic Oncology Group (GOG) 213 trial randomly assigned 485 patients with recurrent platinum-sensitive ovarian or primary peritoneal cancer who had a complete response to front-line chemotherapy, a treatment-free interval longer than six months, and investigator-determined resectable disease to secondary surgical cytoreduction followed by platinum-based chemotherapy or platinum-based chemotherapy alone (
         <a class="drug drug_general" data-topicid="9202" href="/z/d/drug information/9202.html" rel="external">
          carboplatin
         </a>
         and
         <a class="drug drug_general" data-topicid="9735" href="/z/d/drug information/9735.html" rel="external">
          paclitaxel
         </a>
         with or without
         <a class="drug drug_general" data-topicid="8683" href="/z/d/drug information/8683.html" rel="external">
          bevacizumab
         </a>
         or carboplatin and
         <a class="drug drug_general" data-topicid="8487" href="/z/d/drug information/8487.html" rel="external">
          gemcitabine
         </a>
         with or without bevacizumab) [
         <a href="#rid44">
          44
         </a>
         ]. Complete gross resection (R0) was achieved in two-thirds of patients who underwent surgery, comparable with the rate in the DESKTOP III study. Most patients had a platinum-free interval &gt;12 months, and the median platinum-free interval was 20.4 months.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         At 48 months median follow-up, the HR for death was similar for both groups (surgery versus no surgery HR 1.29, 95% CI 0.97-1.72), which corresponded to a median overall survival after surgery versus chemotherapy of 50.6 and 64.7 months, respectively. The HR for disease progression or death was also similar (surgery versus no surgery HR 0.82, 95% CI 0.66-1.01), with median progression-free survival after surgery versus chemotherapy of 18.9 and 16.2 months, respectively.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         In addition, 9 percent of patients in the surgical group experienced surgical morbidity, and one patient died from postoperative complications. Although patient-reported quality of life decreased postoperatively, it did not differ significantly between the groups after recovery.
        </p>
        <p>
        </p>
        <p>
         The discordant results from DESKTOP III and SOC-1 compared with GOG 213 need to be evaluated further, and final data on OS in SOC-1 are essential since only interim analysis data have been reported. The favorable effect on progression-free survival is a poor surrogate since secondary cytoreduction removes the disease that would be monitored. One major difference among the trials is the substantial difference in use of
         <a class="drug drug_general" data-topicid="8683" href="/z/d/drug information/8683.html" rel="external">
          bevacizumab
         </a>
         (84 percent in GOG 213, approximately 23 percent in DESKTOP III, and &lt;10 percent in SOC-1). Another difference is the patient selection criteria, which were stricter in DESKTOP III and SOC-1 than in GOG 213. The positive AGO score used in DESKTOP III required a complete gross resection (R0) at primary surgery; SOC-1 predicted the feasibility of complete resection with computerized scoring and imaging. Despite these differences, all three trials demonstrated survival benefit with secondary surgical cytoreduction when complete gross resection was achieved.
        </p>
        <p>
         While awaiting final results of SOC-1 to further inform our approach, we continue to reserve secondary cytoreduction for patients with ovarian cancer that recurred at least six months after platinum-based chemotherapy and that has a limited number of involved sites, as described in the table  (
         <a class="graphic graphic_table graphicRef126425" href="/z/d/graphic/126425.html" rel="external">
          table 1
         </a>
         ).
        </p>
        <p class="headingAnchor" id="H1070848908">
         <span class="h2">
          Quality of life
         </span>
         <span class="headingEndMark">
          —
         </span>
         Quality of life is not discussed in the vast majority of the studies evaluating the role of surgical cytoreduction for recurrent ovarian cancer. In the DESKTOP III trial (see
         <a class="local">
          'Overall survival'
         </a>
         above), results of quality-of-life analyses did not show any between-group differences in the surgery versus chemotherapy alone groups [
         <a href="#rid42">
          42
         </a>
         ]. A retrospective study including 54 patients undergoing surgical cytoreduction followed by chemotherapy or chemotherapy alone also showed similar quality-of-life scores on questionnaires at three and six months after treatment, with the exception of pain and constipation, which were worse at three months in the surgery group [
         <a href="#rid45">
          45
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H1258952790">
         <span class="h1">
          FOLLOW-UP
         </span>
         <span class="headingEndMark">
          —
         </span>
         After surgical cytoreduction for recurrent ovarian cancer, post-treatment surveillance is similar to that after primary cytoreductive surgery. These patients must be monitored for possible tertiary or quaternary recurrence. (See
         <a class="medical medical_review" href="/z/d/html/17007.html" rel="external">
          "Approach to survivors of epithelial ovarian, fallopian tube, or peritoneal carcinoma", section on 'Post-treatment surveillance'
         </a>
         .)
        </p>
        <p>
         Systemic chemotherapy should be administered adjuvantly. (See
         <a class="medical medical_review" href="/z/d/html/16755.html" rel="external">
          "Medical treatment for relapsed epithelial ovarian, fallopian tube, or peritoneal cancer: Platinum-sensitive disease"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H1854525470">
         <span class="h1">
          SOCIETY GUIDELINE LINKS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See
         <a class="medical medical_society_guidelines" href="/z/d/html/119533.html" rel="external">
          "Society guideline links: Ovarian, fallopian tube, and peritoneal cancer"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H566579433">
         <span class="h1">
          SUMMARY AND RECOMMENDATIONS
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Scope
         </strong>
         – The majority of ovarian cancer patients experience recurrence of disease. Most patients with recurrent ovarian cancer are treated with chemotherapy alone. Surgical treatment is reserved for a select group of patients. (See
         <a class="local">
          'Introduction'
         </a>
         above and
         <a class="local">
          'Overall survival'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Goals
         </strong>
         – The goal of additional cytoreductive surgery is to prolong survival by resecting all visible disease (complete gross [R0] resection). The goal of surgery for bowel obstruction is palliative: to improve quality of life. (See
         <a class="local">
          'Scope and goals of surgery'
         </a>
         above and
         <a class="local">
          'Procedure'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Patient selection
         </strong>
         – Patient selection is critical in the decision to proceed with secondary debulking. In general, candidates for secondary cytoreduction are patients with limited sites of recurrence and disease-free interval greater than 6 to 12 months  (
         <a class="graphic graphic_table graphicRef126425" href="/z/d/graphic/126425.html" rel="external">
          table 1
         </a>
         ). For such patients, we suggest secondary surgical cytoreduction plus chemotherapy rather than chemotherapy alone (
         <a class="grade" href="https:///uptodate/show/grade_6" rel="external">
          Grade 2C
         </a>
         ). Risk models, imaging findings, and possibly laparoscopy are utilized to identify these patients. (See
         <a class="local">
          'Candidates'
         </a>
         above and
         <a class="local">
          'Predicting successful disease resection'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Overall survival
         </strong>
         – In observational studies of patients with recurrent ovarian cancer, complete secondary cytoreduction plus platinum-based chemotherapy was associated with longer overall survival than chemotherapy alone, but these studies are limited by selection bias. Data from randomized trials are limited and conflicting. (See
         <a class="local">
          'Overall survival'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Quality of life
         </strong>
         – While quality of life is not discussed in the vast majority of studies evaluating the role of surgical cytoreduction for recurrent ovarian cancer, it appears that quality of life is similar for those undergoing surgery or chemotherapy alone; pain and constipation may be worse in patients undergoing surgery. (See
         <a class="local">
          'Quality of life'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Post-treatment surveillance
         </strong>
         – After surgical cytoreduction for recurrent ovarian cancer, post-treatment surveillance is similar to that after primary cytoreductive surgery. These patients must be monitored for possible tertiary or quaternary recurrence. (See
         <a class="local">
          'Follow-up'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H272603482">
         <span class="h1">
          ACKNOWLEDGMENT
         </span>
         <span class="headingEndMark">
          —
         </span>
         The editorial staff at UpToDate acknowledges William J Mann, Jr, MD; Eva Chalas, MD, FACOG, FACS; and Fidel A Valea, MD, who contributed to previous versions of this topic review.
        </p>
       </div>
       <div class="headingAnchor" id="references">
        <ol id="reference">
         <li>
          <a class="nounderline abstract_t">
           Suh DH, Kim HS, Chang SJ, Bristow RE. Surgical management of recurrent ovarian cancer. Gynecol Oncol 2016; 142:357.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Zang RY, Harter P, Chi DS, et al. Predictors of survival in patients with recurrent ovarian cancer undergoing secondary cytoreductive surgery based on the pooled analysis of an international collaborative cohort. Br J Cancer 2011; 105:890.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Chi DS, McCaughty K, Diaz JP, et al. Guidelines and selection criteria for secondary cytoreductive surgery in patients with recurrent, platinum-sensitive epithelial ovarian carcinoma. Cancer 2006; 106:1933.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Eisenkop SM, Friedman RL, Spirtos NM. The role of secondary cytoreductive surgery in the treatment of patients with recurrent epithelial ovarian carcinoma. Cancer 2000; 88:144.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tay EH, Grant PT, Gebski V, Hacker NF. Secondary cytoreductive surgery for recurrent epithelial ovarian cancer. Obstet Gynecol 2002; 99:1008.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gadducci A, Iacconi P, Cosio S, et al. Complete salvage surgical cytoreduction improves further survival of patients with late recurrent ovarian cancer. Gynecol Oncol 2000; 79:344.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Scarabelli C, Gallo A, Carbone A. Secondary cytoreductive surgery for patients with recurrent epithelial ovarian carcinoma. Gynecol Oncol 2001; 83:504.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gronlund B, Lundvall L, Christensen IJ, et al. Surgical cytoreduction in recurrent ovarian carcinoma in patients with complete response to paclitaxel-platinum. Eur J Surg Oncol 2005; 31:67.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Onda T, Yoshikawa H, Yasugi T, et al. Secondary cytoreductive surgery for recurrent epithelial ovarian carcinoma: proposal for patients selection. Br J Cancer 2005; 92:1026.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Benedetti Panici P, De Vivo A, Bellati F, et al. Secondary cytoreductive surgery in patients with platinum-sensitive recurrent ovarian cancer. Ann Surg Oncol 2007; 14:1136.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Eisenkop SM, Friedman RL, Wang HJ. Secondary cytoreductive surgery for recurrent ovarian cancer. A prospective study. Cancer 1995; 76:1606.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Oksefjell H, Sandstad B, Tropé C. The role of secondary cytoreduction in the management of the first relapse in epithelial ovarian cancer. Ann Oncol 2009; 20:286.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Marmor RA, Kelly KJ, Lowy AM, Baumgartner JM. Laparoscopy is Safe and Accurate to Evaluate Peritoneal Surface Metastasis Prior to Cytoreductive Surgery. Ann Surg Oncol 2016; 23:1461.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Jayakrishnan TT, Zacharias AJ, Sharma A, et al. Role of laparoscopy in patients with peritoneal metastases considered for cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC). World J Surg Oncol 2014; 12:270.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tian WJ, Chi DS, Sehouli J, et al. A risk model for secondary cytoreductive surgery in recurrent ovarian cancer: an evidence-based proposal for patient selection. Ann Surg Oncol 2012; 19:597.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Harter P, du Bois A, Hahmann M, et al. Surgery in recurrent ovarian cancer: the Arbeitsgemeinschaft Gynaekologische Onkologie (AGO) DESKTOP OVAR trial. Ann Surg Oncol 2006; 13:1702.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Harter P, Sehouli J, Reuss A, et al. Prospective validation study of a predictive score for operability of recurrent ovarian cancer: the Multicenter Intergroup Study DESKTOP II. A project of the AGO Kommission OVAR, AGO Study Group, NOGGO, AGO-Austria, and MITO. Int J Gynecol Cancer 2011; 21:289.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cowan RA, Eriksson AGZ, Jaber SM, et al. A comparative analysis of prediction models for complete gross resection in secondary cytoreductive surgery for ovarian cancer. Gynecol Oncol 2017; 145:230.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hollis RL, Carmichael J, Meynert AM, et al. Clinical and molecular characterization of ovarian carcinoma displaying isolated lymph node relapse. Am J Obstet Gynecol 2019; 221:245.e1.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Zivanovic O, Chi DS, Zhou Q, et al. Secondary Cytoreduction and Carboplatin Hyperthermic Intraperitoneal Chemotherapy for Platinum-Sensitive Recurrent Ovarian Cancer: An MSK Team Ovary Phase II Study. J Clin Oncol 2021; 39:2594.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Shih KK, Chi DS, Barakat RR, Leitao MM Jr. Tertiary cytoreduction in patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer: an updated series. Gynecol Oncol 2010; 117:330.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Fotopoulou C, Richter R, Braicu IE, et al. Clinical outcome of tertiary surgical cytoreduction in patients with recurrent epithelial ovarian cancer. Ann Surg Oncol 2011; 18:49.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Fotopoulou C, Zang R, Gultekin M, et al. Value of tertiary cytoreductive surgery in epithelial ovarian cancer: an international multicenter evaluation. Ann Surg Oncol 2013; 20:1348.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Manning-Geist BL, Chi DS, Long Roche K, et al. Tertiary cytoreduction for recurrent ovarian carcinoma: An updated and expanded analysis. Gynecol Oncol 2021; 162:345.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Shih KK, Chi DS, Barakat RR, Leitao MM Jr. Beyond tertiary cytoreduction in patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer. Gynecol Oncol 2010; 116:364.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Fotopoulou C, Savvatis K, Kosian P, et al. Quaternary cytoreductive surgery in ovarian cancer: does surgical effort still matter? Br J Cancer 2013; 108:32.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Roh HJ, Kim DY, Joo WD, et al. Hepatic resection as part of secondary cytoreductive surgery for recurrent ovarian cancer involving the liver. Arch Gynecol Obstet 2011; 284:1223.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Yoon SS, Jarnagin WR, Fong Y, et al. Resection of recurrent ovarian or fallopian tube carcinoma involving the liver. Gynecol Oncol 2003; 91:383.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Merideth MA, Cliby WA, Keeney GL, et al. Hepatic resection for metachronous metastases from ovarian carcinoma. Gynecol Oncol 2003; 89:16.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gemignani ML, Chi DS, Gurin CC, et al. Splenectomy in recurrent epithelial ovarian cancer. Gynecol Oncol 1999; 72:407.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Manci N, Bellati F, Muzii L, et al. Splenectomy during secondary cytoreduction for ovarian cancer disease recurrence: surgical and survival data. Ann Surg Oncol 2006; 13:1717.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Chi DS, Phaëton R, Miner TJ, et al. A prospective outcomes analysis of palliative procedures performed for malignant intestinal obstruction due to recurrent ovarian cancer. Oncologist 2009; 14:835.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pothuri B, Vaidya A, Aghajanian C, et al. Palliative surgery for bowel obstruction in recurrent ovarian cancer:an updated series. Gynecol Oncol 2003; 89:306.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pothuri B, Meyer L, Gerardi M, et al. Reoperation for palliation of recurrent malignant bowel obstruction in ovarian carcinoma. Gynecol Oncol 2004; 95:193.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kolomainen DF, Daponte A, Barton DP, et al. Outcomes of surgical management of bowel obstruction in relapsed epithelial ovarian cancer (EOC). Gynecol Oncol 2012; 125:31.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kucukmetin A, Naik R, Galaal K, et al. Palliative surgery versus medical management for bowel obstruction in ovarian cancer. Cochrane Database Syst Rev 2010; :CD007792.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bristow RE, Puri I, Chi DS. Cytoreductive surgery for recurrent ovarian cancer: a meta-analysis. Gynecol Oncol 2009; 112:265.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Al Rawahi T, Lopes AD, Bristow RE, et al. Surgical cytoreduction for recurrent epithelial ovarian cancer. Cochrane Database Syst Rev 2013; :CD008765.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bickell NA, Egorova N, Prasad-Hayes M, et al. Secondary Surgery Versus Chemotherapy for Recurrent Ovarian Cancer. Am J Clin Oncol 2016.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gockley A, Melamed A, Cronin A, et al. Outcomes of secondary cytoreductive surgery for patients with platinum-sensitive recurrent ovarian cancer. Am J Obstet Gynecol 2019; 221:625.e1.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Baek MH, Park EY, Ha HI, et al. Secondary Cytoreductive Surgery in Platinum-Sensitive Recurrent Ovarian Cancer: A Meta-Analysis. J Clin Oncol 2022; 40:1659.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Harter P, Sehouli J, Vergote I, et al. Randomized Trial of Cytoreductive Surgery for Relapsed Ovarian Cancer. N Engl J Med 2021; 385:2123.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Shi T, Zhu J, Feng Y, et al. Secondary cytoreduction followed by chemotherapy versus chemotherapy alone in platinum-sensitive relapsed ovarian cancer (SOC-1): a multicentre, open-label, randomised, phase 3 trial. Lancet Oncol 2021; 22:439.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Coleman RL, Spirtos NM, Enserro D, et al. Secondary Surgical Cytoreduction for Recurrent Ovarian Cancer. N Engl J Med 2019; 381:1929.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Plotti F, Scaletta G, Aloisi A, et al. Quality of Life in Platinum-Sensitive Recurrent Ovarian Cancer: Chemotherapy Versus Surgery Plus Chemotherapy. Ann Surg Oncol 2015; 22:2387.
          </a>
         </li>
        </ol>
       </div>
       <div id="topicVersionRevision">
        Topic 3196 Version 31.0
       </div>
      </div>
      <div class="row">
       <div class="col-12">
        <h4 style="text-align: center;padding: 20px;color: cadetblue;">
         References
        </h4>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27130407" id="rid0" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          1 : Surgical management of recurrent ovarian cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21878937" id="rid1" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          2 : Predictors of survival in patients with recurrent ovarian cancer undergoing secondary cytoreductive surgery based on the pooled analysis of an international collaborative cohort.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16572412" id="rid2" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          3 : Guidelines and selection criteria for secondary cytoreductive surgery in patients with recurrent, platinum-sensitive epithelial ovarian carcinoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10618617" id="rid3" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          4 : The role of secondary cytoreductive surgery in the treatment of patients with recurrent epithelial ovarian carcinoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12052591" id="rid4" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          5 : Secondary cytoreductive surgery for recurrent epithelial ovarian cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11104603" id="rid5" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          6 : Complete salvage surgical cytoreduction improves further survival of patients with late recurrent ovarian cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11733963" id="rid6" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          7 : Secondary cytoreductive surgery for patients with recurrent epithelial ovarian carcinoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15642428" id="rid7" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          8 : Surgical cytoreduction in recurrent ovarian carcinoma in patients with complete response to paclitaxel-platinum.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15770211" id="rid8" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          9 : Secondary cytoreductive surgery for recurrent epithelial ovarian carcinoma: proposal for patients selection.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17195909" id="rid9" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          10 : Secondary cytoreductive surgery in patients with platinum-sensitive recurrent ovarian cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8635065" id="rid10" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          11 : Secondary cytoreductive surgery for recurrent ovarian cancer. A prospective study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18725390" id="rid11" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          12 : The role of secondary cytoreduction in the management of the first relapse in epithelial ovarian cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26542584" id="rid12" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          13 : Laparoscopy is Safe and Accurate to Evaluate Peritoneal Surface Metastasis Prior to Cytoreductive Surgery.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25145962" id="rid13" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          14 : Role of laparoscopy in patients with peritoneal metastases considered for cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC).
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21732142" id="rid14" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          15 : A risk model for secondary cytoreductive surgery in recurrent ovarian cancer: an evidence-based proposal for patient selection.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17009163" id="rid15" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          16 : Surgery in recurrent ovarian cancer: the Arbeitsgemeinschaft Gynaekologische Onkologie (AGO) DESKTOP OVAR trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21270612" id="rid16" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          17 : Prospective validation study of a predictive score for operability of recurrent ovarian cancer: the Multicenter Intergroup Study DESKTOP II. A project of the AGO Kommission OVAR, AGO Study Group, NOGGO, AGO-Austria, and MITO.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28285846" id="rid17" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          18 : A comparative analysis of prediction models for complete gross resection in secondary cytoreductive surgery for ovarian cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31055034" id="rid18" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          19 : Clinical and molecular characterization of ovarian carcinoma displaying isolated lymph node relapse.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34019431" id="rid19" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          20 : Secondary Cytoreduction and Carboplatin Hyperthermic Intraperitoneal Chemotherapy for Platinum-Sensitive Recurrent Ovarian Cancer: An MSK Team Ovary Phase II Study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20189234" id="rid20" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          21 : Tertiary cytoreduction in patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer: an updated series.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20697821" id="rid21" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          22 : Clinical outcome of tertiary surgical cytoreduction in patients with recurrent epithelial ovarian cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23054114" id="rid22" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          23 : Value of tertiary cytoreductive surgery in epithelial ovarian cancer: an international multicenter evaluation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34045053" id="rid23" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          24 : Tertiary cytoreduction for recurrent ovarian carcinoma: An updated and expanded analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19897231" id="rid24" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          25 : Beyond tertiary cytoreduction in patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23321509" id="rid25" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          26 : Quaternary cytoreductive surgery in ovarian cancer: does surgical effort still matter?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21132314" id="rid26" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          27 : Hepatic resection as part of secondary cytoreductive surgery for recurrent ovarian cancer involving the liver.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/14599870" id="rid27" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          28 : Resection of recurrent ovarian or fallopian tube carcinoma involving the liver.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12694649" id="rid28" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          29 : Hepatic resection for metachronous metastases from ovarian carcinoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10053114" id="rid29" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          30 : Splenectomy in recurrent epithelial ovarian cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16957965" id="rid30" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          31 : Splenectomy during secondary cytoreduction for ovarian cancer disease recurrence: surgical and survival data.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19684071" id="rid31" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          32 : A prospective outcomes analysis of palliative procedures performed for malignant intestinal obstruction due to recurrent ovarian cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12713996" id="rid32" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          33 : Palliative surgery for bowel obstruction in recurrent ovarian cancer:an updated series.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15385131" id="rid33" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          34 : Reoperation for palliation of recurrent malignant bowel obstruction in ovarian carcinoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22082991" id="rid34" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          35 : Outcomes of surgical management of bowel obstruction in relapsed epithelial ovarian cancer (EOC).
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20614464" id="rid35" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          36 : Palliative surgery versus medical management for bowel obstruction in ovarian cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18937969" id="rid36" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          37 : Cytoreductive surgery for recurrent ovarian cancer: a meta-analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23450588" id="rid37" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          38 : Surgical cytoreduction for recurrent epithelial ovarian cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27391357" id="rid38" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          39 : Secondary Surgery Versus Chemotherapy for Recurrent Ovarian Cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31207237" id="rid39" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          40 : Outcomes of secondary cytoreductive surgery for patients with platinum-sensitive recurrent ovarian cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/35188810" id="rid40" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          41 : Secondary Cytoreductive Surgery in Platinum-Sensitive Recurrent Ovarian Cancer: A Meta-Analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34874631" id="rid41" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          42 : Randomized Trial of Cytoreductive Surgery for Relapsed Ovarian Cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33705695" id="rid42" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          43 : Secondary cytoreduction followed by chemotherapy versus chemotherapy alone in platinum-sensitive relapsed ovarian cancer (SOC-1): a multicentre, open-label, randomised, phase 3 trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31722153" id="rid43" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          44 : Secondary Surgical Cytoreduction for Recurrent Ovarian Cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25582738" id="rid44" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          45 : Quality of Life in Platinum-Sensitive Recurrent Ovarian Cancer: Chemotherapy Versus Surgery Plus Chemotherapy.
         </p>
        </a>
       </div>
      </div>
     </div>
    </div>
   </section>
  </section>
  <!-- End Main Menu Area -->
  <!-- Start Search Popup Area -->
  <!-- End Footer Area -->
  <!-- Back to top -->
  <a class="scrolltop" href="#top">
   <i class="icofont-hand-drawn-up">
   </i>
  </a>
  <!-- End Back to top -->
  <!-- jQuery Min JS -->
  <!-- Prpper JS -->
  <!-- Bootstrap Min JS -->
  <!-- Classy Nav Min Js -->
  <!-- Owl Carousel Min Js -->
  <!-- Magnific Popup JS -->
  <!-- CounterUp JS -->
  <!-- Waypoints JS -->
  <!-- Form Validator Min JS -->
  <!-- Contact Form Min JS -->
  <!-- Main JS -->
  <!-- Global site tag (gtag.js) - Google Analytics -->
 </body>
</html>
